BLFS BioLife Solutions, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
BLFS Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Instruments & Supplies
Current Price
Live
$24.87
Analyst Target
$32.44
+30.5%
Upside
52W High
$29.62
52W Low
$19.1
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.2B
P/E
N/A
ROE
-5.2%
Profit margin
-3.2%
Debt/Equity
0.06
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
BLFS exhibits a weak fundamental health profile with a Piotroski F-Score of 2/9, indicating significant financial distress risks, and lacks an Altman Z-Score for further validation. Despite strong revenue growth of 31.2% and improving earnings surprises in recent quarters, profitability remains negative with negative ROE and ROA. The stock trades at a high valuation with a Forward P/E of 155.44 and Price/Sales of 11.96, above sector averages, while insider selling activity raises caution. Analysts maintain a strong_buy consensus, but this is not yet supported by robust cash flow or consistent earnings generation.
Key Strengths
Strong year-over-year revenue growth of 31.20%, outpacing many peers in the healthcare sector
High gross margin of 64.28%, indicating strong pricing power and cost control in core operations
Exceptional recent earnings surprise performance, averaging +207.14% over the last four quarters
Low debt burden with a Debt/Equity ratio of just 0.06, providing financial flexibility
High liquidity position with a current ratio of 4.66 and quick ratio of 3.31, suggesting solid short-term solvency
Key Risks
Very weak Piotroski F-Score of 2/9, signaling poor financial health and high risk of operational deterioration
Negative profitability across all metrics: profit margin (-3.20%), operating margin (-0.32%), ROE (-5.25%), and ROA (-0.73%)
Lack of Altman Z-Score prevents definitive assessment of bankruptcy risk, but negative earnings and ROE are concerning
Insiders have been consistently selling shares, with $1.28M in sell transactions over the past 6 months and no buys
Valuation multiples are extremely high (Forward P/E: 155.44, Price/Sales: 11.96), making the stock vulnerable to multiple contraction
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
37
Weak
35
72
50
28
0
AI Verdict
Cautiously optimistic due to growth and margin strength, but constrained by weak profitability and financial health
Key drivers: High revenue growth and gross margin, Recent earnings beat streak, Low leverage and high liquidity, Weak Piotroski score and negative returns, Bearish insider activity
Confidence
68%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 3.37 is reasonable for a growth-oriented healthcare company
Watchpoints
- Forward P/E of 155.44 is extremely high
- No Graham Number available, suggesting lack of earnings stability
- Price/Sales of 11.96 is well above sector average of ~75.69% revenue growth companies
Future
72/100
Ref Growth rates
Positives
- Revenue growth of 31.20% YoY is strong
- Earnings growth of +150% YoY indicates rapid improvement
- Analyst target price of $32.44 implies 30.8% upside
Watchpoints
- Forward P/E suggests high expectations already priced in
- No Q/Q growth data available for confirmation
Past
50/100
Ref Historical trends
Positives
- Recent quarters show consistent earnings beats (3 of last 4)
Watchpoints
- History of large earnings misses and negative EPS prior to 2024
- Long-term price performance weak: -40.8% over 5 years
Health
28/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 4.66 and quick ratio of 3.31 indicate strong liquidity
Watchpoints
- Piotroski F-Score of 2/9 indicates severe financial weakness
- Negative ROE (-5.25%) and ROA (-0.73%)
- No Altman Z-Score available, increasing uncertainty
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid (yield N/A)
- Dividend strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$24.87
Analyst Target
$32.44
Upside/Downside
+30.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BLFS and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BLFS
BioLife Solutions, Inc.
Primary
|
-40.8% | -0.5% | -10.7% | +10.1% | -2.1% | +1.8% |
|
BFLY
Butterfly Network, Inc.
Peer
|
-76.9% | +59.4% | +8.9% | +128.9% | +14.2% | +8.4% |
|
ALVO
Alvotech
Peer
|
-69.0% | -74.3% | -69.0% | -56.8% | -28.4% | -13.5% |
|
ABCL
AbCellera Biologics Inc.
Peer
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
|
AKTS
Aktis Oncology, Inc.
Peer
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
155.44
PEG Ratio
N/A
P/B Ratio
3.37
P/S Ratio
11.96
EV/Revenue
11.38
EV/EBITDA
-598.62
Market Cap
$1.2B
Profitability
Profit margins and return metrics
Profit Margin
-3.2%
Operating Margin
-0.32%
Gross Margin
64.28%
ROE
-5.25%
ROA
-0.73%
Growth
Revenue and earnings growth rates
Revenue Growth
+31.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.06
Low debt
Current Ratio
4.66
Strong
Quick Ratio
3.31
Excellent
Cash/Share
$1.64
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-02
$N/A
2025-11-06
$0.01
+200.0% surprise
2025-08-07
$0.01
+220.0% surprise
2025-05-08
$0.04
+201.4% surprise
Healthcare Sector Comparison
Comparing BLFS against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-5.25%
This Stock
vs
-52.77%
Sector Avg
-90.1%
(Below Avg)
Profit Margin
-3.2%
This Stock
vs
-20.78%
Sector Avg
-84.6%
(Weaker)
Debt to Equity
0.06
This Stock
vs
6.16
Sector Avg
-99.1%
(Less Debt)
Revenue Growth
31.2%
This Stock
vs
137.39%
Sector Avg
-77.3%
(Slower)
Current Ratio
4.66
This Stock
vs
3.36
Sector Avg
+38.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BLFS
BioLife Solutions, Inc.
|
NEUTRAL | $1.2B | - | -5.2% | -3.2% | $24.87 | |
|
BFLY
Butterfly Network, Inc.
|
NEUTRAL | $1.14B | - | -41.4% | -90.3% | $4.51 | |
|
ALVO
Alvotech
|
BEARISH | $1.08B | 15.09 | -% | 12.1% | $3.47 | |
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | |
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-06 | MATHEW ABY J | Officer | Sale | 405 | $10,364 |
| 2026-01-06 | BERARD TODD C.J. | Officer | Sale | 344 | $8,803 |
| 2026-01-06 | FOSTER KAREN A | Officer | Sale | 335 | $8,573 |
| 2026-01-06 | AEBERSOLD SARAH | Officer | Sale | 241 | $6,167 |
| 2026-01-06 | WICHTERMAN TROY | Chief Financial Officer | Sale | 990 | $25,334 |
| 2025-12-15 | AEBERSOLD SARAH | Officer | Sale | 946 | $23,295 |
| 2025-12-15 | DUROSS AMY | Director | Sale | 2,000 | $49,200 |
| 2025-12-09 | BERARD TODD C.J. | Officer | Sale | 358 | $8,997 |
| 2025-12-09 | FOSTER KAREN A | Chief Operating Officer | Sale | 519 | $13,042 |
| 2025-12-09 | MATHEW ABY J | Officer | Sale | 631 | $15,857 |
| 2025-12-09 | WICHTERMAN TROY | Chief Financial Officer | Sale | 1,033 | $25,959 |
| 2025-12-04 | WICHTERMAN TROY | Chief Financial Officer | Sale | 30,000 | $771,600 |
| 2025-11-26 | DUROSS AMY | Director | Sale | 4,000 | $108,000 |
| 2025-11-25 | BERARD TODD C.J. | Officer | Sale | 351 | $9,386 |
| 2025-11-25 | FOSTER KAREN A | Chief Operating Officer | Sale | 415 | $11,097 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
9 analysts
HC Wainwright & Co.
2025-12-29
Buy
Buy
HC Wainwright & Co.
2025-11-24
Buy
Buy
HC Wainwright & Co.
2025-08-08
Buy
Buy
Past News Coverage
Recent headlines mentioning BLFS from our newsroom.
Newest → oldest
No matching news yet.